Inclusion Criteria:  Patients over 19 years of age Patients diagnosed with gastrointestinal (stomach, esophageal, direct colon, liver, pancreatic biliary tract) cancer and lung cancer Patients receiving first- or second-line palliative chemotherapy ECOG PS 0-2  Patients who were classified as normal, precachexia or cachexia according to the cachexia classification criteria  Normal: Neither pre-cachexia Nor cachexia Precachexia: Weight loss ≤5%, Anorexia or glucose intolerance in last 6 months Cachexia: Weight loss >5%, or BMI <20 with weight loss >2% in last 6 months Adequate organ functions  Exclusion Criteria:  Patients with history of heart failure or currently being treated for heart failure Patients with SBP of 160 mmHg or higher or DBP of 100 mmHg or higher despite antihypertensive medication Patients with or have a history of bronchial asthma Patients with bowel obstruction Patients who have taken appetite stimulants or anabolic or anti-catabolic agents (eg. Megestrol acetate, progestational agents, etc.) within 30 days prior to the study enrollment Patients who received steroid treatment (> 10 mg/d prednisolone or equivalent) within 3 months prior to the study enrollment Patients who have taken nonsteroidal anti-inflammatory drugs or aspirin continuously for more than 1 week Patients with problems with taking non-steroidal anti-inflammatory drugs (NSAIDs) or those with uncontrolled diabetes due to digestive system diseases (gastric ulcer, gastrointestinal bleeding, etc.) Patients who are pregnant or breastfeeding, who have not used proper contraception (oral, injection, infusion or hormonal contraceptive methods, intrauterine devices and blocking methods) Patients who are taking anticoagulants (e.g. warfarin or heparin) Patients who have difficulty in oral administration Patients who have a history of hypersensitivity reactions such as asthma, hives, or allergic reactions to drugs containing ibuprofen, aspirin, and other nonsteroidal anti-inflammatory drugs (including COX-2 inhibitors) Patients who showed clinically significant hypersensitivity reactions to investigational products